menu
    • menu
    [{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"Dimerix","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Nephrology","graph2":"Phase II","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"Dimerix \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Dimerix \/ IQVIA"},{"orgOrder":0,"company":"CSL","sponsor":"Prim. Priv. Doz. Dr. Daniel Cejka","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL \/ Prim. Priv. Doz. Dr. Daniel Cejka","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Prim. Priv. Doz. Dr. Daniel Cejka"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSL

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            CSL

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacopan

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VFMCRP and Chemocentryx Provide Topline Results from Accolade Trial of Avacopan in C3 Glomerulopathy Including...

                            Details : ChemoCentryx plans to discuss the results with the U.S. Food and Drug Administration as it has obtained evidence of avacopan’s ability to improve renal function, being well-tolerated in C3G patients to date.

                            Product Name : Tavneos

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : Avacopan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Amgen Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dimerix

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Dimerix

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propagermanium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            DIMERIX’s DMX-200 Posts Strong Results in Kidney Disease Trial

                            Details : Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients, 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 29, 2020

                            Lead Product(s) : Propagermanium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dimerix

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Dimerix

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propagermanium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesa...

                            Details : Propagermanium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glomerulosclerosis, Focal Segmental.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2018

                            Lead Product(s) : Propagermanium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dimerix

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Dimerix

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propagermanium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan

                            Details : Propagermanium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetic Nephropathies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 13, 2018

                            Lead Product(s) : Propagermanium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : IQVIA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CSL

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            CSL

                            Australia arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Prim. Priv. Doz. Dr. Daniel Cejka

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum

                            Details : Sucroferric Oxyhydroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 04, 2017

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Prim. Priv. Doz. Dr. Daniel Cejka

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.